Clonal Progenitor Re-Derivation for Prenatal Brown Fat Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to differentiate pluripotent stem cells into site-specific progenitor and terminally differentiated cell types, particularly brown adipose tissue (BAT) cells, that exhibit a prenatal or pre-fetal pattern of gene expression and express markers such as UCP1, C19orf80, and adiponectin, while avoiding expression of COX7A1, and to develop biocompatible matrices for effective engraftment and therapeutic delivery of these cells.
Innovation Solution
The method involves isolating and expanding clonal embryonic progenitor cell lines from pluripotent stem cells in the presence of noggin or other TGF-beta family inhibitors, which are then differentiated to express UCP1, C19orf80, and adiponectin, and are used in conjunction with biocompatible matrices for engraftment and therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If pluripotent stem cells are differentiated into brown adipose tissue cells using conventional methods, then BAT cells can be generated, but the cells exhibit adult or fetal gene expression patterns (COX7A1 positive) instead of prenatal patterns, reducing therapeutic effectiveness
Solution Approach 1:
The patent applies preliminary action by treating pluripotent stem cells with TGF-beta inhibitors (noggin or SB431542) during early differentiation stages (days 0-5) before the cells commit to the brown adipose tissue lineage. This preliminary inhibition of TGF-beta signaling prevents the expression of COX7A1 and other adult markers, programming the cells to maintain a prenatal gene expression pattern that enhances their therapeutic effectiveness for metabolic disorders.
2Manufacturing precision
If clonal embryonic progenitor cell lines are isolated and expanded, then site-specific BAT cells can be produced, but the differentiation process becomes complex and requires multiple factors and conditions
Solution Approach 1:
The patent utilizes parameter changes by systematically varying the concentration and timing of TGF-beta inhibitors during the differentiation process. By optimizing the inhibitor concentration (e.g., 100 ng/mL noggin or 10 µM SB431542) and treatment duration, the method achieves precise control over cell fate decisions, enabling the production of site-specific BAT cells while managing process complexity through defined parameter ranges.
3Ease of manufacture
If pluripotent stem cells are differentiated without TGF-beta inhibition, then differentiation proceeds naturally, but the resulting cells express COX7A1 and lack prenatal gene expression patterns
Solution Approach 1:
The patent introduces TGF-beta inhibitors (noggin or SB431542) as intermediary substances that block TGF-beta signaling during early differentiation. This intermediary action prevents the activation of pathways leading to COX7A1 expression, thereby controlling gene expression patterns without completely overriding the natural differentiation process. The inhibitors act as mediators between the differentiation signals and the target gene expression outcome.
4Reliability
If brown adipose tissue cells are generated for therapeutic use, then metabolic disorders can be treated, but the cells must be engrafted into the patient which requires biocompatible matrices and delivery systems
Solution Approach 1:
The patent employs biocompatible matrices with multi-functionality that serve multiple purposes: providing structural support for cell engraftment, delivering differentiation factors, and facilitating cell adhesion and survival. These universal matrices can be used across different therapeutic applications and patient types, reducing the need for application-specific customization while maintaining high engraftment efficiency and therapeutic effect.
Data Source
AI summary
Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.